The Clinical Development of Thalildomide as an Angiogenesis Inhibitor Therapy for Prostate Cancer
Abstract
Significant progress has been made in the understanding of key factors that regulate the cell-cell interaction in the context of the microenvironment of prostate cancer. This includes technical advances in getting information from small amounts of tissue to forward understanding of the molecular determinants of progression. We have developed tissue micro arrays (TMAs), and stained them for candidate factors implicated in stromal epithelial interaction and have demonstrated that they are expressed in the context of Thalidomide treated patients. This information will be used to compare these results to the expression patterns in similar prostate cancers not exposed to Thalidomide. We are requesting a no-cost extension of 6 months to allow completion of the planned studies. A formal letter will be sent separately.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2005
- Accession Number
- ADA454836
Entities
People
- Christopher J. Logothetis
Organizations
- The University of Texas MD Anderson Cancer Center